SEC Declares Pfizer’ Registration Statement Effective For Acquisition Of Wyeth
Transaction expected to close during the fourth quarter of 2009
Pfizer has announced that the US Securities and Exchange Commission (SEC) has declared effective Pfizer’ Registration Statement on Form S-4. The Form S-4 registers with the SEC Pfizer’s common stock to be issued in connection with the pending acquisition of Wyeth.
In addition, the form S-4 includes Wyeth’s Proxy Statement for its annual meeting of stockholders to be held on July 20, 2009, at which Wyeth’s stockholders will vote on the merger agreement with Pfizer.
Completion of this transaction remains subject to the following: expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the US, governmental and regulatory approvals, approval by the stockholders of Wyeth, and other usual and customary closing conditions. Subject to the satisfaction of the foregoing conditions, it is expected that the transaction will close at the end of the third quarter or during the fourth quarter of 2009.
Related Insight
Suppliers Directory
Fleming Europe - Business-to-Business Events and Training
Serving the need for information and knowledge sharing for over six years, Fleming Europe has become one of the most important business intelligence companies delivering quality business-to-business (B2B) events worldwide.
Contract Research & Services > Contract Research > Suppliers
Kuecept - Concept Formulation Design
Kuecept Ltd is a specialist pharmaceutical contract research organisation supporting clients with the early phase development of low solubility, poorly bioavailable compounds. Our patented drug delivery technologies and formulation expertise in oral and parenteral dosage form design and development are used to fast track compounds through preclinical efficacy studies and toxicity testing and into clinic with robust, stable and improved performance products.
Suppliers
CCL Label - Global Healthcare and Pharmaceutical Packaging Solutions
CCL Label is a Global Manufacturer of Pharmaceutical and Healthcare packaging. With 20 healthcare sites globally, we offer the expertise, trained personnel and dedicated production capabilities to ensure that your pharmaceutical/healthcare labelling is accurate, secure and meets all FDA requirements and current Good Manufacturing Practices (GMP)
Suppliers
Enamine - Small Molecule Compound Libraries, Diversity/Focus Sets, Fragments, Custom Synthesis from Integrated Hit Finding to Lead Optimization in Drug Discovery Under Flexible Business Models
Enamine Ltd (est. 1991) is a privately owned chemical company, expert in synthesis of Building Blocks and derived small molecular weight compound libraries for drug discovery needs.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Biomolecular Screening and ADMET services
Published by Enamine
White Papers
Right Place, Right Time
Published by Centrical Global Limited
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.